Despite the use of clinicopathological variables such as symptoms, pathology results (Gleason Grade Groups (GG), number of biopsy cores, maximum percentage of core involvement) and serum prostate-specific antigen (PSA) levels for risk stratification, accurately differentiating between indolent and aggressive forms of cancer remains a major challenge [4]. The gene discussed is KLK3; the disease is cancer.